Anzhelika Vorobyeva

1.4k citations

73 papers · 1.0k indexed · h-index 20

Co-authors: Vladimir Tolmachev Anna Orlova Javad Garousi Bogdan Mitran Sergey M. Deyev Sara S. Rinne Maryam Oroujeni Mohamed Altai
Topics: Monoclonal and Polyclonal Antibodies Research (61 papers)Radiopharmaceutical Chemistry and Applications (48 papers)HER2/EGFR in Cancer Research (38 papers)
Cited by: Radiology, Nuclear Medicine and Imaging Oncology Biotechnology
Journals: SHILAP Revista de lepidopterologíaPLoS ONE Biomaterials
Partner nations: Sweden Russia Netherlands

In The Last Decade

Anzhelika Vorobyeva

70 papers receiving 996 citations

Peers

Countries citing papers authored by Anzhelika Vorobyeva

Since Specialization

Citations

This map shows the geographic impact of Anzhelika Vorobyeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anzhelika Vorobyeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anzhelika Vorobyeva more than expected).

Fields of papers citing papers by Anzhelika Vorobyeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anzhelika Vorobyeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anzhelika Vorobyeva. The network helps show where Anzhelika Vorobyeva may publish in the future.

Co-authorship network of co-authors of Anzhelika Vorobyeva

This figure shows the co-authorship network connecting the top 25 collaborators of Anzhelika Vorobyeva. A scholar is included among the top collaborators of Anzhelika Vorobyeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anzhelika Vorobyeva. Anzhelika Vorobyeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture 2025 ·International Journal of Molecular Sciences ·Vladimir Tolmachev,Anzhelika Vorobyeva,(unknown),Javad Garousi,(unknown),Torbjörn Gräslund,(unknown),Alexey Schulga,Е. В. Коновалова,Anna Orlova,Sergey M. Deyev,Maryam Oroujeni	1
2	Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts 2024 ·ACS Pharmacology & Translational Science ·Jie Zhang,Sara S. Rinne,(unknown),(unknown),E. Bjorklund,Ayman Abouzayed,Stefan Ståhl,John Löfblom,Anna Orlova,Torbjörn Gräslund,Anzhelika Vorobyeva	2
3	Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab 2023 ·Cancers ·(unknown),Tianqi Xu,Anzhelika Vorobyeva,(unknown),(unknown),Anna Orlova,Fredrik Y. Frejd,Vladimir Tolmachev	13
4	Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs 2023 ·Journal of Controlled Release ·(unknown),Tianqi Xu,(unknown),Jie Zhang,(unknown),(unknown),М. В. Белоусов,(unknown),Maryam Oroujeni,Anna Orlova,Vladimir Tolmachev,Torbjörn Gräslund,Anzhelika Vorobyeva	11
5	Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model 2023 ·International Journal of Molecular Sciences ·Tianqi Xu,Alexey Schulga,Е. В. Коновалова,Sara S. Rinne,Hongchao Zhang,Olga Vorontsova,Anna Orlova,Sergey M. Deyev,Vladimir Tolmachev,Anzhelika Vorobyeva	3
6	Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart 2022 ·Pharmaceutics ·Javad Garousi,Tianqi Xu,(unknown),Olga Vorontsova,Sophia Hober,Anna Orlova,Vladimir Tolmachev,Torbjörn Gräslund,Anzhelika Vorobyeva	3
7	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules 2022 ·Biomedicines ·Sara S. Rinne,(unknown),(unknown),Ayman Abouzayed,(unknown),Anzhelika Vorobyeva,John Löfblom,Stefan Ståhl,Anna Orlova,Torbjörn Gräslund	5
8	Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer 2022 ·International Journal of Molecular Sciences ·(unknown),Evgenii Plotnikov,(unknown),(unknown),(unknown),(unknown),Roman Zelchan,Alexey Schulga,Е. В. Коновалова,Anzhelika Vorobyeva,Javad Garousi,Torbjörn Gräslund,М. В. Белоусов,Vladimir Tolmachev,Sergey M. Deyev	4
9	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 2022 ·Pharmaceutics ·Tianqi Xu,Jie Zhang,Maryam Oroujeni,(unknown),(unknown),М. В. Белоусов,Anna Orlova,Vladimir Tolmachev,Anzhelika Vorobyeva,Torbjörn Gräslund	7
10	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT 2022 ·Pharmaceutics ·(unknown),(unknown),Tianqi Xu,(unknown),Anna Orlova,Maryam Oroujeni,Sara S. Rinne,Vladimir Tolmachev,Anzhelika Vorobyeva,Torbjörn Gräslund	7
11	Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis 2022 ·Pharmaceutics ·(unknown),(unknown),(unknown),Anzhelika Vorobyeva,(unknown),(unknown),(unknown),Leendert J. van den Bos,Robert Naasz,(unknown),Anna Orlova,Caroline Ekblad,Vladimir Tolmachev,Fredrik Y. Frejd	5
12	Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy 2022 ·International Journal of Molecular Sciences ·Vladimir Tolmachev,(unknown),Maryam Oroujeni,Sergey M. Deyev,Е. В. Коновалова,Alexey Schulga,Sarah Lindbo,Sophia Hober,Olga Bragina,Anna Orlova,Anzhelika Vorobyeva	5
13	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model 2021 ·Cancers ·Tianqi Xu,Anzhelika Vorobyeva,Alexey Schulga,Е. В. Коновалова,Olga Vorontsova,(unknown),Torbjörn Gräslund,Л. А. Таширева,Anna Orlova,Vladimir Tolmachev,Sergey M. Deyev	11
14	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy 2021 ·Pharmaceutics ·(unknown),Tianqi Xu,(unknown),Maryam Oroujeni,Jie Zhang,Anzhelika Vorobyeva,Olga Vorontsova,С. В. Вторушин,Vladimir Tolmachev,Torbjörn Gräslund,Anna Orlova	11
15	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein 2021 ·Pharmaceutics ·Javad Garousi,(unknown),(unknown),Tianqi Xu,Anzhelika Vorobyeva,Maryam Oroujeni,Anna Orlova,Sophia Hober,Torbjörn Gräslund,Vladimir Tolmachev	8
16	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution 2021 ·Pharmaceutics ·(unknown),Tianqi Xu,Jie Zhang,Vladimir Tolmachev,Maryam Oroujeni,Anna Orlova,Torbjörn Gräslund,Anzhelika Vorobyeva	14
17	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 2021 ·Cancers ·Sergey M. Deyev,Tianqi Xu,(unknown),Alexey Schulga,Е. В. Коновалова,Javad Garousi,Sara S. Rinne,(unknown),(unknown),Torbjörn Gräslund,Anna Orlova,Vladimir Tolmachev,Anzhelika Vorobyeva	12
18	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model 2020 ·Cancers ·Tianqi Xu,(unknown),Anzhelika Vorobyeva,Maryam Oroujeni,Anna Orlova,Vladimir Tolmachev,Torbjörn Gräslund	25
19	Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 2019 ·International Journal of Oncology ·Anzhelika Vorobyeva,(unknown),Е. В. Коновалова,(unknown),Bogdan Mitran,Javad Garousi,Sara S. Rinne,(unknown),Anna Orlova,Sergey M. Deyev,Vladimir Tolmachev	27
20	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 2019 ·European Journal of Pharmaceutics and Biopharmaceutics ·(unknown),Javad Garousi,Sarah Lindbo,Anzhelika Vorobyeva,Mohamed Altai,Maryam Oroujeni,Bogdan Mitran,Anna Orlova,Sophia Hober,Vladimir Tolmachev	21

About Anzhelika Vorobyeva

Anzhelika Vorobyeva is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Biotechnology, having authored 73 papers that have together received 1.0k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (61 papers), Radiopharmaceutical Chemistry and Applications (48 papers) and HER2/EGFR in Cancer Research (38 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (799 citations), Oncology (499 citations) and Biotechnology (48 citations). Anzhelika Vorobyeva has collaborated with scholars based in Sweden, Russia and Netherlands. Frequent co-authors include Vladimir Tolmachev, Anna Orlova, Javad Garousi, Bogdan Mitran, Sergey M. Deyev, Sara S. Rinne, Maryam Oroujeni, Mohamed Altai, Alexey Schulga and Tianqi Xu. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact